New drug offers gentler path to cancer cure, could spare patients brutal chemo

This study tested if a newer, targeted drug called brentuximab vedotin could replace a harsh, multi-drug chemotherapy regimen (called ICE) as the first step before a stem cell transplant for patients whose Hodgkin lymphoma had returned or didn't respond to initial treatment. The goal was to see if this gentler approach could effectively shrink the cancer with fewer side effects, using a special PET scan to decide if the stronger ICE chemo was still needed. The trial involved 66 patients with CD30-positive Hodgkin lymphoma who had relapsed after their first treatment.